ArticleClinical and experimental reproductive medicine2026
Average oocyte quality index as a method for scoring dysmorphic oocytes in women with ovarian endometrioma undergoing in vitro fertilization and its correlation with ovarian reserve.
Article in Clinical and experimental reproductive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigated whether the average oocyte quality index (AOQI), used as a dysmorphic oocyte scoring system, is higher in women with ovarian endometrioma than in those with unexplained infertility or diminished ovarian reserve (DOR).
methodsWe included 92 intracytoplasmic sperm injection cycles in which one to five metaphase II oocytes were obtained, and the AOQI was calculated in each cycle. Cycles were grouped according to the indication for in vitro fertilization: current or recurrent endometrioma (34 cycles), unexplained infertility (26 cycles), and DOR (32 cycles). DOR was defined by a serum anti-Müllerian hormone (AMH) level <1.0 ng/mL. The AOQI was compared among the three groups, and the relationship between serum AMH levels and AOQI was also analyzed.
resultsThe median AOQI value was significantly higher in the endometrioma group (1.50) compared to the unexplained infertility group (1.00) (p=0.037), but not compared to the DOR group (1.42). Overall, serum AMH level showed an inverse correlation with the AOQI (r=-0.242, p=0.02). Serum AMH level was also inversely correlated with the AOQI in the endometrioma group (r=-0.429, p=0.011), but not in the unexplained infertility and DOR groups. Multiple linear regression analysis demonstrated that serum AMH levels remained inversely correlated with the AOQI (B=-0.176; 95% confidence interval, -0.327 to -0.024; p=0.024), whereas the presence of endometrioma was not a significant factor.
conclusionThe AOQI in the ovarian endometrioma group was higher compared to the unexplained infertility group, and this difference appeared to arise primarily from reduced ovarian reserve rather than the direct impact of endometrioma itself. Serum AMH levels showed an inverse correlation with AOQI, emphasizing the central role of ovarian reserve in determining oocyte quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.